Cargando…
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057925/ https://www.ncbi.nlm.nih.gov/pubmed/35529539 http://dx.doi.org/10.1016/j.jvacx.2022.100165 |
_version_ | 1784698008853544960 |
---|---|
author | Casado, José L. Vizcarra, Pilar Haemmerle, Johannes Velasco, Héctor Martín-Hondarza, Adrián Rodríguez-Domínguez, Mario J. Velasco, Tamara Martín, Sara Romero-Hernández, Beatriz Fernández-Escribano, Marina Vallejo, Alejandro |
author_facet | Casado, José L. Vizcarra, Pilar Haemmerle, Johannes Velasco, Héctor Martín-Hondarza, Adrián Rodríguez-Domínguez, Mario J. Velasco, Tamara Martín, Sara Romero-Hernández, Beatriz Fernández-Escribano, Marina Vallejo, Alejandro |
author_sort | Casado, José L. |
collection | PubMed |
description | Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4(+) T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination. |
format | Online Article Text |
id | pubmed-9057925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90579252022-05-02 Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 Casado, José L. Vizcarra, Pilar Haemmerle, Johannes Velasco, Héctor Martín-Hondarza, Adrián Rodríguez-Domínguez, Mario J. Velasco, Tamara Martín, Sara Romero-Hernández, Beatriz Fernández-Escribano, Marina Vallejo, Alejandro Vaccine X Short communication Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4(+) T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination. Elsevier 2022-05-02 /pmc/articles/PMC9057925/ /pubmed/35529539 http://dx.doi.org/10.1016/j.jvacx.2022.100165 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Short communication Casado, José L. Vizcarra, Pilar Haemmerle, Johannes Velasco, Héctor Martín-Hondarza, Adrián Rodríguez-Domínguez, Mario J. Velasco, Tamara Martín, Sara Romero-Hernández, Beatriz Fernández-Escribano, Marina Vallejo, Alejandro Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title | Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title_full | Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title_fullStr | Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title_full_unstemmed | Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title_short | Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2 |
title_sort | pre-existing t cell immunity determines the frequency and magnitude of cellular immune response to two doses of mrna vaccine against sars-cov-2 |
topic | Short communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057925/ https://www.ncbi.nlm.nih.gov/pubmed/35529539 http://dx.doi.org/10.1016/j.jvacx.2022.100165 |
work_keys_str_mv | AT casadojosel preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT vizcarrapilar preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT haemmerlejohannes preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT velascohector preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT martinhondarzaadrian preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT rodriguezdominguezmarioj preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT velascotamara preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT martinsara preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT romerohernandezbeatriz preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT fernandezescribanomarina preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 AT vallejoalejandro preexistingtcellimmunitydeterminesthefrequencyandmagnitudeofcellularimmuneresponsetotwodosesofmrnavaccineagainstsarscov2 |